Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY)

RDY on New York Consolidated

35.26USD
20 Nov 2017
Change (% chg)

$-0.65 (-1.81%)
Prev Close
$35.91
Open
$35.00
Day's High
$35.35
Day's Low
$34.98
Volume
167,721
Avg. Vol
367,214
52-wk High
$47.75
52-wk Low
$29.83

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Labs ‍launches clofarabine injection in U.S.
Tuesday, 14 Nov 2017 02:33am EST 

Nov 14 (Reuters) - Dr.Reddy's Laboratories Ltd ::Says ‍launch of clofarabine injection in U.S. market​.  Full Article

DR. REDDY'S LABORATORIES LAUNCHES GENERIC AZACITIDINE FOR INJECTION IN CANADIAN MARKET
Thursday, 2 Nov 2017 10:33am EDT 

Nov 2 (Reuters) - Dr.Reddy's Laboratories Ltd :DR REDDY'S LABORATORIES ANNOUNCES THE LAUNCH OF GENERIC AZACITIDINE FOR INJECTION IN THE CANADIAN MARKET.GENERIC AZACITIDINE FOR INJECTION 100 MG/VIAL, A BIOEQUIVALENT GENERIC VERSION OF VIDAZA IS APPROVED BY HEALTH CANADA​.  Full Article

India's Dr.Reddy's Laboratories Sept-qtr consol PAT down about 1 pct
Tuesday, 31 Oct 2017 02:01am EDT 

Oct 31 (Reuters) - Dr.Reddy's Laboratories Ltd ::Sept quarter consol net profit after tax 3.05 billion rupees versus 3.09 billion rupees last year.Consensus forecast for sept quarter consol profit was 2.88 billion rupees.Sept quarter consol net sales 34.91 billion rupees versus 35.29 billion rupees last year.Expect to see results from products launched in U.S. during first half of the fiscal‍​.  Full Article

Dr.Reddy's Labs says FDA completes ‍audit of co's Telangana facilities with no observations​
Thursday, 21 Sep 2017 03:00am EDT 

Sept 21 (Reuters) - Dr.Reddy's Laboratories Ltd ::FDA completes ‍audit of co's Telangana custom pharmaceutical services facility, technology development centre with no observations​.  Full Article

Dr.Reddy's Laboratories says Regulatory Authority of Germany concludes audit of facility
Friday, 8 Sep 2017 01:36am EDT 

Sept 8 (Reuters) - Dr.Reddy's Laboratories Ltd :Regulatory Authority of Germany concluded audit of formulations manufacturing facility in Vishakapatnam.Says products manufactured at facility not currently exported to EU.Audit of formulations manufacturing facility concluded with zero critical and 6 major observations.Says co to submit corrective and preventive action plan to authorities.Facility's compliance with CAPA and other regulations will be reviewed again by regulator by Nov 2018.  Full Article

Dr. Reddy's Laboratories announces launch of two drugs in U.S. market
Wednesday, 6 Sep 2017 02:04am EDT 

Sept 6 (Reuters) - Dr.Reddy's Laboratories Ltd :Says announces launch of bupropion hydrochloride extended-release tablets, USP (XL) in U.S. Market.Says announces launch of metaxalone tablets, USP in U.S. market.  Full Article

Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material
Friday, 1 Sep 2017 05:32am EDT 

Sept 1 (Reuters) - Dr.Reddy's Laboratories Ltd :Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus.Co confirms reaching settlement with Vivus.Overall impact on co's financials of settlement of patent disputes with Vivus not likely to be material.  Full Article

Dr.Reddy's Labs says ruling in favour of co on generic version of Suboxone doesn't infringe U.S. patents as asserted by Indivior
Friday, 1 Sep 2017 04:07am EDT 

Sept 1 (Reuters) - Dr.Reddy's Laboratories Ltd ::U.S. court ruling in favour of co on generic version of suboxone doesn't infringe U.S. patents as asserted by Indivior .  Full Article

Indivior to appeal court rulings ANDA litigation
Friday, 1 Sep 2017 02:00am EDT 

Sept 1 (Reuters) - Indivior Plc :INDIVIOR TO APPEAL COURT RULINGS ANDA LITIGATION.INDIVIOR RESPONDS TO COURT RULINGS IN ANDA LITIGATION AND ANNOUNCES INTENTION TO APPEAL.US DISTRICT COURT FOR DISTRICT OF DELAWARE HAS FOUND ASSERTED CLAIMS OF U.S. PATENT NOS. 8,017,150; 8,603,514; 8,900,497 VALID.US DISTRICT COURT FOR DISTRICT OF DELAWARE FOUND DR. REDDY'S DOES NOT INFRINGE ANY ASSERTED CLAIMS OF PATENTS.US DISTRICT COURT FOR DISTRICT OF DELAWARE FOUND WATSON (ACTAVIS) AND PAR DO NOT INFRINGE ASSERTED CLAIM OF '497 PATENT.COURT HAS ALSO ISSUED A SEPARATE RULING DENYING WATSON'S AND PAR'S MOTIONS TO REOPEN COURT'S JUNE 2016 JUDGMENT.COURT'S RULING ENJOINING MARKETING APPROVAL AND SALE OF WATSON'S AND PAR'S PROPOSED GENERIC PRODUCTS UNTIL EXPIRATION OF '514 PATENT IN 2024 REMAINS IN PLACE.  Full Article

Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation
Wednesday, 30 Aug 2017 04:05pm EDT 

Aug 30 (Reuters) - Vivus Inc ::Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation.Vivus Inc - ‍settlement permits Dr. Reddy's to begin selling a generic version of qsymia on June 1, 2025, or earlier under certain circumstances​.Vivus - ‍in event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of generic version of qsymia​.  Full Article

BRIEF-Dr.Reddy's Labs ‍launches clofarabine injection in U.S.

* Says ‍launch of clofarabine injection in U.S. market​ Source text: http://bit.ly/2zBoR7i Further company coverage: